Cemile Jakupoglu,1,
Stéphanie G. Moreno,1
Stefanie Lippl,1
Ana Banjac,1
Manuela Schneider,2
Heike Beck,1
Antonis K. Hatzopoulos,1
Ursula Just,1
Fred Sinowatz,3
Wolfgang Schmahl,4
Kenneth R. Chien,5
Wolfgang Wurst,6
Georg W. Bornkamm,1,
and
Markus Brielmeier2,
Institute of Clinical Molecular Biology and Tumour Genetics, GSF Research Centre for Environment and Health,1 Department of Veterinary Anatomy II,3 Institute of Veterinary Pathology, Ludwig-Maximilian University of Munich, Munich,4 Department of Comparative Medicine,2 Institute of Developmental Genetics, GSF Research Centre for Environment and Health, Neuherberg, Germany,6 Institute of Molecular Medicine, University of California at San Diego School of Medicine, La Jolla, California5
Received 18 February 2004/ Returned for modification 21 April 2004/ Accepted 22 July 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Thioredoxins are small redox-active proteins with an essential function in DNA metabolism and repair, transcription, and cell-cell communication (1). Acting through peroxiredoxins, they also efficiently protect cells from oxidative damage (27). Cytosolic (Trx1) and mitochondrial (Trx2) thioredoxins are required for proliferation and protection from apoptosis during early embryogenesis (26). Moreover, in chicken B cells, Trx2 is critically involved in the regulation of mitochondrion-dependent apoptosis (37). More recently, heart-specific overexpression of dominant-negative Trx1 was shown to be associated with increased oxidative stress and cardiac hypertrophy in mice (39).
Trx activities are governed by thioredoxin reductases (TrxRs) that, in turn, use NADPH/H+ as the reducing agent (23). TrxRs are members of the pyridine nucleotide-disulfide oxidoreductase family, form homodimers, and possess two interacting redox-active centers. The C-terminal redox center contains a catalytically important selenocysteine (SeCys) (9, 17, 41). In mammals, three TrxRs are knownone cytosolic (TrxR1) (8), one mitochondrial (TrxR2) (7), and one testis-specific GSH-TrxR (33) each encoded by individual genes. In contrast to their well-studied biochemical properties, little is known about the individual contribution of the different TrxRs in living organisms or about possible redundancies among the different redox systems. To dissect the complex network of redox metabolism in vivo, we have established mice deficient for mitochondrial TrxR2. To overcome possible embryonic lethality, as observed in Trx1- and Trx2-null mice, and to investigate TrxR2 function in specific organs and at defined time points, we used a conditional ablation strategy. Ubiquitous deletion of TrxR2 results in embryonic lethality at embryonic day 13 (E13). TrxR2/ embryos are severely anemic and exhibit a marked thinning of the ventricular heart wall. To further dissect the contribution of the two major defects in the overall phenotype, we generated mice with cardiac cell-specific inactivation of the TrxR2 gene. These mice developed fatal dilated cardiomyopathy and died shortly after birth. Analysis of fibroblasts isolated from TrxR2/ embryos revealed a critical role of TrxR2 in the removal of toxic ROS species and the maintenance of mitochondrial integrity.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Mice were kept under standard conditions with food and water ad libitum (Altromin GmbH, Lage, Germany). All animal experiments were performed in compliance with the German animal welfare law and have been approved by the institutional committee on animal experimentation and the government of Upper Bavaria.
RNA isolation and semiquantitative reverse transcription-PCR (RT-PCR). Total RNA was isolated from homogenized embryonic tissue by using peqGOLDTriFast (peqLab, Erlangen, Germany). DNase-treated total RNA (DNase I, RNase I free, catalog no. 776785; Roche, Mannheim, Germany) was reverse transcribed by using a reverse transcription system (Promega Corp., Madison, Wis.). Primer pairs specific for Aldolase (Aldolase1/2, AGCTGTCTGACATCGCTCACCG/CACATACTGGCAGCGCTTCAAG) and TrxR2(TrxR2E6/10, CAGCTTTGTGGATGAGCACACAGTTCG/GATCCTCCCAAGTGACCTGCAGCTGG; and TrxR2E15/18, TTCACGGTGGCGGATAGGGATGC/TGCCCAGGCCATCATCATCTGACG) were used to detect the transcripts.
In situ end labeling (ISEL). Detection of apoptotic cells was performed with the ApopTag kit (S7100; Serologicals Corp., Norcross, Ga.) on PFA-fixed (4% [wt/vol] paraformaldehyde [PFA] in phosphate-buffered saline), paraffin-embedded sections according to the manufacturer's instructions. Digoxigenin-deoxynucleoside triphosphate-labeled cells were incubated with an anti-digoxigenin peroxidase conjugate and visualized with 3,3'-diaminobenzidine (DAB, SK-4100; Vector Laboratories, Inc., Burlingame, Calif.).
Immunohistochemistry. (i) LacZ staining. Upon standard pretreatment and blocking with M.O.M. blocking reagent (M.O.M Immunodetection Kit, PK-2200; Vector Laboratories), cryosections were incubated overnight with an anti-ß-galactosidase monoclonal antibody (1:50; MAB1802; Chemicon International, Inc., Temecula, Calif.). Visualization of avidin-biotin complexes was performed with 3-amino-9-ethylcarbazole (SK-4200; Vector Laboratories).
(ii) PCNA staining. PFA-fixed paraffin-embedded sections were incubated for 1 h at 37°C with anti-PCNA monoclonal antibody (1:200; PC10; Dako, Glostrup, Denmark) and visualized with DAB.
(iii) Double antibody-apoptosis labeling. Cryosections were incubated overnight at 4°C with a rat anti-mouse CD45 antibody (1:20; catalog no. 550539; BD Pharmingen, San Jose, Calif.). In the case of rat anti-K8 or -K18 antibodies, initial incubation was performed for 90 min at 37°C (1:10; Troma1 and Troma2 [kindly provided by Solange Magre, CNRS/Université Pierre et Marie Curie, Paris, France, and Rolf Kemler, Max Planck Institute, Freiburg, Germany]). Sections were subsequently incubated with a secondary biotinylated antibody for 1 h at room temperature. After avidin-biotin complex reaction was performed (ABC alkaline phosphatase staining kit, AK-5000; Vector Laboratories), bound antibodies were visualized with a substrate for alkaline phosphatase (Vector Blue, SK-5300; Vector Laboratories). Sections were washed and postfixed in cold ethanol-acetic acid (2:1) at 20°C, the endogenous peroxidase activity was blocked with 3% (vol/vol) H2O2, and the sections were subjected to the standard ISEL procedure.
Electron microscopy. Hearts were isolated and immediately fixed in 2.5% glutaraldehyde-2% PFA in 0.1 M sodium cacodylate buffer (pH 7.2) for 24 h, rinsed three times in the same buffer, and postfixed in 1% osmium tetroxide-1.5% potassium ferrocyanide in potassium cacodylate buffer for 2 h. Samples were washed three times, dehydrated, and embedded in Propylenoxyd and Polyembed 812 (Plano, Wetzlar, Germany). Ultrathin sections (60 nm) were stained with uranyl acetate and lead acetate and then examined on a Zeiss 902 electron microscope at 80 kV.
BrdU incorporation and detection. 5-Bromodeoxyuridine (BrdU; catalog no. 100171; ICN Biomedicals, Aurora, Ohio) was injected intraperitoneally in pregnant mice at E13.0 at a dose of 100 mg/kg of body weight. After 2 h, isolated embryos were fixed in PFA and embedded in paraffin. Incorporated BrdU was visualized by immunohistochemistry with an anti-BrdU monoclonal antibody (catalog no. 1170376; Roche Diagnostics Corp.) and a secondary biotinylated antibody (ABC peroxidase staining).
Mouse embryonic fibroblast (MEF) culture. Embryos were isolated from pregnant mice at E12.5, the body trunk was dissected away from other structures and then treated with trypsin, treated with DNase, minced with a syringe, and cultivated under standard conditions in Dulbecco modified Eagle medium (Invitrogen GmbH, Karlsruhe, Germany) with 10% fetal calf serum (FCS), glutamine, and penicillin-streptomycin. Buthionine sulfoximine (BSO; Sigma-Aldrich, Taufkirchen, Germany) was used at a 50 µM final concentration.
Staining of MEFs. Cell nuclei were stained with 1 µM Hoechst 33342 (Sigma-Aldrich), and the mitochondria were stained with 0.5 µM MitoTracker Green FM (Molecular Probes, Inc., Oreg.). RedoxSensor Red CC-1 was used according to the manufacturer's protocol (2) (Molecular Probes). Stained cells were assessed with a Zeiss Axiovert 200 M microscope (Carl Zeiss, Jena, Germany) and Openlab software (version 3.0; Improvision, Coventry, United Kingdom).
CFU assays. CFU assays were performed as described previously (30). In brief, livers from E12.5 embryos were prepared, minced with a syringe in Iscove modified Dulbecco medium (including 20% FCS), centrifuged, and resuspended for hemolysis in 1 volume of medium without FCS and 1 volume of 2x hemolysis buffer (1.5 M NH4Cl, 0.1 M KHCO3, and 1 mM EDTA in 500 ml [pH 7.4] with KOH). The hemolysis step was repeated twice. Cells were plated at equal cell numbers on 35-mm dishes containing methylcellulose, 10% bovine serum albumin (catalog no. 652237; Roche), 20% FCS (pretested), 1% penicillin-streptomycin, 1% glutamine, 50 µM ß-mercaptoethanol, and cytokines (100 U of mouse interleukin-3 [IL-3] conditioned medium, 2 U of erythropoietin, 10 ng of stem cell factor, 10 ng of FLIT ligand, 10 ng of thrombopoietin, 10 ng of granulocyte-macrophage colony-stimulating factor, and 10 ng of IL-6/ml). After 1 week of incubation, colonies with >50 cells were counted and subdivided into granulocytes, macrophages, mixed colonies (more than three different cell types), granulocytes and macrophages, and burst-forming units that were additionally visualized by benzidine staining (0.1 volume of benzidine, 0.1 volume of H2O2, and 0.5 volume of H2O).
| RESULTS |
|---|
|
|
|---|
To study the TrxR2 expression pattern, we designed a conditional lacZ knockin approach into the TrxR2 locus (Fig. 1E). A translational and transcriptional stop/internal ribosomal entry site-ß-galactosidase(lacZ) cassette was placed in the 3'-nontranscribed region of the TrxR2 gene. This brings LacZ under the control of the endogenous TrxR2 promoter upon Cre-mediated removal of exons 15 to 18, including the transcriptional stop signal (derived from the mouse phosphoglycerine kinase gene). Immunohistochemistry of TrxR2+/(lacZ-k.i.) embryos with an anti-lacZ antibody revealed strong expression in the embryonic heart, especially in the myocardium and atrial walls, and to a lower extent in the embryonic liver (Fig. 1F to I). These findings are consistent with mRNA expression data obtained from adult tissues (21).
Embryonic lethality caused by TrxR2 deficiency. Intercross of TrxR2+/ mice did not yield TrxR2/ offspring (of 137 viable offspring, 33.6% were genotypically WT and 66.4% hemizygous). Genotyping of littermates at different days of gestation revealed that TrxR2/ embryos died between E12.5 and E13.5. TrxR2/ embryos were reduced in size and had an anemic appearance (Fig. 2A). The blood vessels of the yolk sac and the embryo proper were markedly less supplied with blood (Fig. 2B to E), and the bloodstream velocity was slower in living TrxR2/ embryos at E13.0 (data not shown). The anemic appearance of the TrxR2/ embryos and the comparable high expression of TrxR2 in embryonic heart and liver suggested a crucial role of TrxR2 in the respective organs.
|
|
, collagen IV, erbB3, vWF, and VE-cadherin did not reveal any abnormal patterns in TrxR2TrxR2/minus;/TrxR2/minus; embryos (data not shown). Moreover, we did not observe any defects in vessel formation of placenta and yolk sacs of TrxR2/ embryos (data not shown). We conclude that reduced proliferation, rather than loss, of cardiomyocytes is the cause of the thinning of the ventricular myocard in TrxR2TrxR2/minus;/TrxR2/minus; embryos. TrxR2 is required for fetal blood cell formation. We examined whether the anemic phenotype in TrxR2TrxR2/minus;/TrxR2/minus; embryos is due to reduced heart function or whether it is caused by perturbed hematopoiesis in the liver, the main site of fetal hematopoiesis after E11 (6). Noticeable was the pleiomorphic and spongiform appearance of liver tissue in TrxR2TrxR2/minus;/TrxR2/minus; embryos, suggesting perturbed proliferation and/or increased apoptosis of hepatocytes and/or hematopoietic cells (Fig. 3G and H). BrdU and PCNA staining of embryonic liver sections did not reveal any major differences (data not shown), whereas ISEL staining showed augmented apoptosis in the liver of TrxR2TrxR2/minus;/TrxR2/minus; embryos (Fig. 3I and K). Double staining, including ISEL, blood cell marker CD45, and hepatocyte markers keratins 8 and 18, revealed that mainly blood cells were affected by the loss of TrxR2 (Fig. 3L to N). CFU assays with liver cells isolated from E12.5 embryos were carried out to investigate whether hematopoietic differentiation is perturbed. In CFU assays, the composition of blood cell colonies was unaltered (Fig. 4A). However, TrxR2TrxR2/minus;/TrxR2/minus; colonies were markedly smaller (Fig. 4B to E), indicating that reduced blood cell formation is the cause of the severe anemic phenotype of TrxR2TrxR2/minus;/TrxR2/minus; embryos.
|
-glutamyl-cysteinyl-synthetase that catalyzes the rate-limiting step in GSH synthesis, only WT but not KO MEFs were able to survive and proliferate (Fig. 4H). To test whether increased levels of ROS in TrxR2TrxR2/minus;/TrxR2/minus; MEFs are responsible for the failure of cell survival when GSH synthesis is inhibited, we stained MEFs with the RedoxSensor Red CC-1 dye. In the presence of BSO, RedoxSensor Red CC-1 was predominantly localized in lysosomes of WT cells and in mitochondria of TrxR2TrxR2/minus;/TrxR2/minus; cells (Fig. 4I to L). Treatment of cells with the antioxidant N-acetylcysteine (NAC) rescued TrxR2TrxR2/minus;/TrxR2/minus; MEFs from BSO-induced apoptosis (Fig. 4H and M). These data indicate that under limiting GSH conditions TrxR2 is indispensable for sustaining cell survival in fibroblasts.
Heart-specific inactivation of TrxR2 leads to fatal dilated cardiomyopathy.
Targeted disruption of genes such as retinoid X receptor
(5) and the cytokine receptor gp130 (40) has suggested that these genes participate in heart and blood development. However, cardiomyocyte-specific inactivation of the respective genes did not support the conclusions drawn from the complete KO experiments (3, 10). To rule out the possibility that the failure in heart development is the consequence of a primary defect of TrxR2 deficiency in hematopoietic cells, TrxR2 was deleted specifically in cardiomyocytes by using the MLC2a-Cre transgenic mouse line (38). TrxR2+/ mice were first crossed with MLC2a-Cre mice and, subsequently, TrxR2+/,Tg[MLC2a-Cre] and TrxR2fl/fl mice were mated to obtain TrxR2fl/,Tg[MLC2a-Cre] mice. Mice that had both copies of the TrxR2 gene deleted in a cardiac tissue-specific manner showed clinical features of congestive heart failure, including generalized edema, liver congestion, globular heart shape, and atrial dilatation, and died within several hours after birth (data not shown). Histological examination revealed dilated heart cavities and thinning of the ventricular myocardium (Fig. 5B and C). We observed, at higher magnifications, severe distortion in the morphology of myocardial cells, such as pycnotic nuclei, cytoplasmic vacuolization, and reduced cross-striation (Fig. 5D to G). Electron microscopic analyses of neonatal hearts showed severe swelling and destruction of mitochondrial cristae in cardiomyocytes of cardiac tissue-restricted TrxR2-deficient mice (Fig. 5H to L). Vessel formation of yolk sac and placenta, as well as development of coronary arteries, as assessed by histological and immunohistochemical examination (vWF staining), was not affected by heart-specific inactivation of TrxR2 (data not shown). This demonstrates that TrxR2 is not only essential for normal embryonic hematopoiesis but also plays a crucial role in the maintenance of mitochondrial integrity in cardiomyocytes and is therefore indispensable for proper heart function of newborn mice.
|
| DISCUSSION |
|---|
|
|
|---|
Anticipating that loss of TrxR2 might be associated with embryonic death, we used the cre/loxP technology for the generation of TrxR2 KO mice. Cre-mediated excision of the last four exons leads to the removal of the final 100 amino acids including the C terminally located redox-center consisting of Cys-SeCys-Gly. Mutational and biochemical studies have previously shown that SeCys is essential for the enzymatic function of TrxRs (9, 17, 41). Also, this approach deemed necessary because the 5' region of TrxR2 overlaps with the first exon of the catechol-o-methyltransferase gene, and there is also alternative first exon usage in the TrxR2 gene (22, 34).
We found that during development TrxR2 is mainly expressed in the embryonic heart and liver, reflecting the adult situation (22). This expression profile associates TrxR2 function with organs characterized by high metabolic activity and further corroborates a crucial role for TrxR2 in the control of harmful intracellular ROS.
Ubiquitous deletion of the TrxR2 gene leads to embryonic lethality at E13. The phenotypic characteristics of TrxR2TrxR2/minus;/TrxR2/minus; embryos reflected the expression pattern of TrxR2 in normal development. TrxR2-null embryos were highly anemic and smaller compared to WT littermates. Histological examination of the heart revealed that the ventricular walls and the trabeculae were thinner in KO mice than in WT and TrxR2+/ mice. The number of ISEL-positive cells was increased in the liver but not in the heart. In CFU assays established from fetal liver at E13, the size of all types of hematopoietic colonies was dramatically reduced, whereas hematopoietic differentiation was not affected by TrxR2 deficiency.
Outgrowth of TrxR2TrxR2/minus;/TrxR2/minus; MEFs in tissue culture was also impaired but not to the same extent as observed for hematopoietic cells. TrxR2TrxR2/minus;/TrxR2/minus; fibroblasts could be propagated in vitro; they were, however, much more sensitive to oxidative stress imposed to the cells by GSH depletion than TrxR2+/+ and TrxR2+/ cells. These data indicate that under standard cell culture conditions hematopoietic cells are more dependent on TrxR2 than fibroblasts. Several mechanisms, either alone or in combination, may account for the proposed hierarchy in TrxR2 dependence. Cells may differ in their ability to cope with oxygen radicals due to different degrees of pathway redundancy and/or overall antioxidant capacity. Alternatively, oxygen radical production of different cell types may vary greatly due to differences in their cellular metabolism. Finally, different cell types may differ widely in their intrinsic susceptibility versus resistance to oxygen radical-induced apoptosis due to different expression patterns of pro- and antiapoptotic proteins. The hematopoietic system is well known for its selective sensitivity to ionizing irradiation. Our finding that TrxR2 KO mice die of anemia at day 13 of embryonic development may thus emphasize the particular susceptibility of hematopoietic cells to oxygen radical-induced apoptosis. This interpretation is in line with the fact that deletion of Trx2 in the chicken B-cell line DT40 leads to oxygen-radical induced apoptosis mediated by cytochrome c release and caspase-3 activation (37).
The TrxR2 inactivation phenotype is less severe than the one observed in the KO mice of Trx2, the main substrate of TrxR2. Trx2/ mice die at E10.5 due to massive apoptosis (26). This suggests that other enzymes, such as, for example, TrxR1 or the GSH-dependent redox system, can partially substitute for the TrxR2 deficiency.
Besides the defect in hematopoiesis, TrxR2 KO mice exhibited morphological changes in the heart. To discriminate whether TrxR2 plays an intrinsic role in heart development and function or whether the defect in heart morphology is a consequence of the defect in hematopoiesis, we bypassed the hematopoietic phenotype and established cardiac tissue-restricted TrxR2-deficient mice. These mice died shortly after birth from dilated cardiomyopathy and congestive heart failure. High-magnification and ultrastructural examination revealed severe distortion in the morphology of cardiomyocytes, i.e., pycnotic nuclei, partial loss of cross-striation, swelling of the mitochondria, and destruction of mitochondrial cristae. In contrast to the severe changes in morphology, no signs of apoptosis were detected in the myocardium by ISEL staining. Difficulties in detecting apoptotic cells in morphologically severely perturbed heart tissue have also been noted by others. Narula et al. found that cardiomyocytes of patients with idiopathic dilated or ischemic cardiomyopathy exhibit severe mitochondrial swelling and accumulation of cytochrome c in the cytosol in the absence of apoptotic changes (24). Likewise, the apoptotic index as defined by the TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) assay was found to be very low in models of chronic heart failure (12, 18). We suggest that cardiac tissue-restricted TrxR2 KO mice die of congestive heart failure due to mitochondrial dysfunction of cardiomyocytes before DNA degradation and cell death of cardiomyocytes can be detected to a significant extent.
The fact that mice with cardiac tissue-specific deletion of TrxR2 die shortly after birth has two implications. First, it indicates that the defect in heart morphology observed in TrxR2TrxR2/minus;/TrxR2/minus; mice at E13 is not only a consequence of the hematopoietic defect. It demonstrates for the first time that loss of one member of the Trx/TrxR system is indispensable for normal heart development and function. Second, lethality in complete TrxR2TrxR2/minus;/TrxR2/minus; embryos is delayed from E13 until birth in mice with a cardiac tissue-specific deletion of TrxR2. This suggests that the heart-specific defect observed in TrxR2TrxR2/minus;/TrxR2/minus; mice at E13 is not limiting on its own for survival during embryonic development. However, TrxR2 deficiency in cardiomyocytes becomes fatal when an entirely self-sustaining circulatory system has to be maintained by the heart. It is conceivable that in mice with ubiquitous deletion of TrxR2, anemia and the heart-specific defect enhance each other and, thus, may lead to an earlier lethal compound phenotype compared to the respective tissue specific deletions. To clarify this issue, it would be necessary to generate a hematopoiesis-specific KO of TrxR2.
Using transgenic approaches, Yamamoto et al. demonstrated that Trx1 is involved in cardiac myocyte growth of mice (39). Heart-specific overexpression of a dominant-negative form of Trx1 led to increased oxidative stress in cardiomyocytes associated with cardiac hypertrophy, whereas overexpression of WT Trx1 reduced the extent of ROS-induced hypertrophy in response to pressure overload. Since the dominant-negative Trx1 may impair Trx2 activity as well, a putative contribution of Trx2 in protection of cardiomyocytes in this model seems likely. The perinatal lethality in our heart-specific TrxR2 KO model precludes at present a detailed study of heart function parameters. Crossing the conditional TrxR2 KO mice with the inducible heart-specific MERCreMER mice might generate a valuable tool for studying the impact of TrxR2 deficiency on adult heart physiology (32).
A first indication that selenium is essential for heart function came from patients suffering from Keshan disease, a selenium deficiency disease endemic in China. Severely selenium-depleted humans show dilated congestive cardiomyopathy resembling the histopathologic phenotype of Friedreich's cardiomyopathy (28) and the phenotype observed in the TrxR2TrxR2/minus;/TrxR2/minus; mice. It is plausible that TrxR2 is the most likely candidate whose function is impaired in Keshan disease due to selenium deficiency. Whether functional impairment of other selenoproteins also contributes to the pathophysiology of this disease remains an open question. It is also noteworthy that TrxR2 is localized to chromosome 22q11, a region deleted in the human haploinsufficiency velo-cardio-facial/DiGeorge Syndrome (VCS/DGS) (13, 19, 20). Hallmarks of VCS/DGS have not been noticed in hemizygous/homozygous or in cardiac tissue-restricted TrxR2 KO mice (data not shown). Further studies will address the question whether loss of one TrxR2 allele may contribute to the compound VCS/DGS phenotype.
| ACKNOWLEDGMENTS |
|---|
This study was supported by the DFG-Priority Programme SPP1087, by Fonds der Chemischen Industrie, and a fellowship from the Humboldt-Stiftung to S.G.M.; by the DFG Priority Programme 1069 "Angiogenesis" (HA 2983/1-2) and the German Human Genome Project (DHGP 9907) to A.K.H.; and by the BMBF to W.W.
| FOOTNOTES |
|---|
M.C., C.J., G.W.B., and M.B. contributed equally to this study. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Chen, C. S., and K. R. Gee. 2000. Redox-dependent trafficking of 2,3,4,5,6-pentafluorodihydrotetramethylrosamine, a novel fluorogenic indicator of cellular oxidative activity. Free Radic. Biol. Med. 28:1266-1278.[CrossRef][Medline]
3. Chen, J., S. W. Kubalak, and K. R. Chien. 1998. Ventricular muscle-restricted targeting of the RXR
gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development 125:1943-1949.[Abstract]
4. Conrad, M., M. Brielmeier, W. Wurst, and G. W. Bornkamm. 2003. Optimized vector for conditional gene targeting in mouse embryonic stem cells. BioTechniques 34:1136-1140.[Medline]
5. Dyson, E., H. M. Sucov, S. W. Kubalak, G. W. Schmid-Schonbein, F. A. DeLano, R. M. Evans, J. Ross, Jr., and K. R. Chien. 1995. Atrial-like phenotype is associated with embryonic ventricular failure in retinoid X receptor alpha/ mice. Proc. Natl. Acad. Sci. USA 92:7386-7390.
6. Dzierzak, E., and A. Medvinsky. 1995. Mouse embryonic hematopoiesis. Trends Genet. 11:359-366.[CrossRef][Medline]
7. Gasdaska, P. Y., M. M. Berggren, M. J. Berry, and G. Powis. 1999. Cloning, sequencing and functional expression of a novel human thioredoxin reductase. FEBS Lett. 442:105-111.[CrossRef][Medline]
8. Gasdaska, P. Y., J. R. Gasdaska, S. Cochran, and G. Powis. 1995. Cloning and sequencing of a human thioredoxin reductase. FEBS Lett. 373:5-9.[CrossRef][Medline]
9. Gorlatov, S. N., and T. C. Stadtman. 1998. Human thioredoxin reductase from HeLa cells: selective alkylation of selenocysteine in the protein inhibits enzyme activity and reduction with NADPH influences affinity to heparin. Proc. Natl. Acad. Sci. USA 95:8520-8525.
10. Hirota, H., J. Chen, U. A. Betz, K. Rajewsky, Y. Gu, J. Ross, Jr., W. Muller, and K. R. Chien. 1999. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97:189-198.[CrossRef][Medline]
11. Hogan, B., R. Beddington, F. Costantini, and E. Lacy. 1994. Manipulating the mouse embryo: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
12. Hughes, S. E. 2003. Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart: fact or epiphenomenon? J. Pathol. 201:181-186.[CrossRef][Medline]
13. Jerome, L. A., and V. E. Papaioannou. 2001. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat. Genet. 27:286-291.[CrossRef][Medline]
14. Joyner, A. L. 2000. Gene targeting: a practical approach, 2nd ed. Oxford University Press, New York, N.Y.
15. Kim, M. R., H. S. Chang, B. H. Kim, S. Kim, S. H. Baek, J. H. Kim, S. R. Lee, and J. R. Kim. 2003. Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell proliferation. Biochem. Biophys. Res. Commun. 304:119-124.[CrossRef][Medline]
16. Kryukov, G. V., S. Castellano, S. V. Novoselov, A. V. Lobanov, O. Zehtab, R. Guigo, and V. N. Gladyshev. 2003. Characterization of mammalian selenoproteomes. Science 300:1439-1443.
17. Lee, S. R., S. Bar-Noy, J. Kwon, R. L. Levine, T. C. Stadtman, and S. G. Rhee. 2000. Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc. Natl. Acad. Sci. USA 97:2521-2526.
18. Li, Z., O. H. Bing, X. Long, K. G. Robinson, and E. G. Lakatta. 1997. Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am. J. Physiol. 272:H2313-H2319.
19. Lindsay, E. A., F. Vitelli, H. Su, M. Morishima, T. Huynh, T. Pramparo, V. Jurecic, G. Ogunrinu, H. F. Sutherland, P. J. Scambler, A. Bradley, and A. Baldini. 2001. Tbx1 haploinsufficiency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 410:97-101.[CrossRef][Medline]
20. Merscher, S., B. Funke, J. A. Epstein, J. Heyer, A. Puech, M. M. Lu, R. J. Xavier, M. B. Demay, R. G. Russell, S. Factor, K. Tokooya, B. S. Jore, M. Lopez, R. K. Pandita, M. Lia, D. Carrion, H. Xu, H. Schorle, J. B. Kobler, P. Scambler, A. Wynshaw-Boris, A. I. Skoultchi, B. E. Morrow, and R. Kucherlapati. 2001. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell 104:619-629.[CrossRef][Medline]
21. Miranda-Vizuete, A., A. E. Damdimopoulos, and G. Spyrou. 1999. cDNA cloning, expression, and chromosomal localization of the mouse mitochondrial thioredoxin reductase gene. Biochim. Biophys. Acta 1447:113-118.[Medline]
22. Miranda-Vizuete, A., and G. Spyrou. 2002. Genomic organization and identification of a novel alternative splicing variant of mouse mitochondrial thioredoxin reductase (TrxR2) gene. Mol. Cells 13:488-492.[Medline]
23. Mustacich, D., and G. Powis. 2000. Thioredoxin reductase. Biochem. J. 346(Pt. 1):1-8.
24. Narula, J., P. Pandey, E. Arbustini, N. Haider, N. Narula, F. D. Kolodgie, B. Dal Bello, M. J. Semigran, A. Bielsa-Masdeu, G. W. Dec, S. Israels, M. Ballester, R. Virmani, S. Saxena, and S. Kharbanda. 1999. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc. Natl. Acad. Sci. USA 96:8144-8149.
25. Neumann, C. A., D. S. Krause, C. V. Carman, S. Das, D. P. Dubey, J. L. Abraham, R. T. Bronson, Y. Fujiwara, S. H. Orkin, and R. A. Van Etten. 2003. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defense and tumour suppression. Nature 424:561-565.[CrossRef][Medline]
26. Nonn, L., R. R. Williams, R. P. Erickson, and G. Powis. 2003. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell. Biol. 23:916-922.
27. Nordberg, J., and E. S. Arner. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31:1287-1312.[CrossRef][Medline]
28. Puccio, H., D. Simon, M. Cossee, P. Criqui-Filipe, F. Tiziano, J. Melki, C. Hindelang, R. Matyas, P. Rustin, and M. Koenig. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27:181-186.[CrossRef][Medline]
29. Schaft, J., R. Ashery-Padan, F. van der Hoeven, P. Gruss, and A. F. Stewart. 2001. Efficient FLP recombination in mouse ES cells and oocytes. Genesis 31:6-10.[CrossRef][Medline]
30. Schroeder, T., S. T. Fraser, M. Ogawa, S. Nishikawa, C. Oka, G. W. Bornkamm, T. Honjo, and U. Just. 2003. Recombination signal sequence-binding protein J
alters mesodermal cell fate decisions by suppressing cardiomyogenesis. Proc. Natl. Acad. Sci. USA 100:4018-4023.
31. Schwenk, F., U. Baron, and K. Rajewsky. 1995. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 23:5080-5081.
32. Sohal, D. S., M. Nghiem, M. A. Crackower, S. A. Witt, T. R. Kimball, K. M. Tymitz, J. M. Penninger, and J. D. Molkentin. 2001. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 89:20-25.
33. Sun, Q. A., L. Kirnarsky, S. Sherman, and V. N. Gladyshev. 2001. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc. Natl. Acad. Sci. USA 98:3673-3678.
34. Sun, Q. A., F. Zappacosta, V. M. Factor, P. J. Wirth, D. L. Hatfield, and V. N. Gladyshev. 2001. Heterogeneity within animal thioredoxin reductases: evidence for alternative first exon splicing. J. Biol. Chem. 276:3106-3114.
35. Suppmann, S., B. C. Persson, and A. Bock. 1999. Dynamics and efficiency in vivo of UGA-directed selenocysteine insertion at the ribosome. EMBO J. 18:2284-2293.[CrossRef][Medline]
36. Tanaka, H., I. Matsumura, S. Ezoe, Y. Satoh, T. Sakamaki, C. Albanese, T. Machii, R. G. Pestell, and Y. Kanakura. 2002. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-
B activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9:1017-1029.[CrossRef][Medline]
37. Tanaka, T., F. Hosoi, Y. Yamaguchi-Iwai, H. Nakamura, H. Masutani, S. Ueda, A. Nishiyama, S. Takeda, H. Wada, G. Spyrou, and J. Yodoi. 2002. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondrion-dependent apoptosis. EMBO J. 21:1695-1703.[CrossRef][Medline]
38. Wettschureck, N., H. Rutten, A. Zywietz, D. Gehring, T. M. Wilkie, J. Chen, K. R. Chien, and S. Offermanns. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of G
q/G
11 in cardiomyocytes. Nat. Med. 7:1236-1240.[CrossRef][Medline]
39. Yamamoto, M., G. Yang, C. Hong, J. Liu, E. Holle, X. Yu, T. Wagner, S. F. Vatner, and J. Sadoshima. 2003. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J. Clin. Investig. 112:1395-1406.[CrossRef][Medline]
40. Yoshida, K., T. Taga, M. Saito, S. Suematsu, A. Kumanogoh, T. Tanaka, H. Fujiwara, M. Hirata, T. Yamagami, T. Nakahata, T. Hirabayashi, Y. Yoneda, K. Tanaka, W. Z. Wang, C. Mori, K. Shiota, N. Yoshida, and T. Kishimoto. 1996. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA 93:407-411.
41. Zhong, L., and A. Holmgren. 2000. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem. 275:18121-18128.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|